A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01725022|
Recruitment Status : Recruiting
First Posted : November 12, 2012
Last Update Posted : December 4, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hematologic Malignancies||Other: Home Care||Not Applicable|
Subjects enrolled in the medical home arm and those serving as concurrent controls will have the following studies:
- Stool collection for analysis at time 0 (prior to preparatory regimen) and then weekly for the first four weeks, at day 60 and 100.
- The PG-SGA, FACT-BMT and other patient-reported symptom instruments will be collected weekly for the first 4 weeks, at day 60, 100 and patients will be required to complete a daily food diary.
- Other assessments for toxicities or GVHD will proceed as per current standard of care, for a total blood draw amount of 100 mls from home care subjects and concurrent controls.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care|
|Study Start Date :||February 2012|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||June 2019|
Experimental: Home Care
This is the arm for patients who receive their transplant care in their homes.
Other: Home Care
This is the interventional arm where patients receive the transplant care in their homes.
No Intervention: Hospital Care
Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
No Intervention: Clinic Care
Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
- Bowel Microbiota [ Time Frame: 100 days ]The bowel microbiota before and during the first 100 days.
- Nutritional status using the PG-SGA assessment tool [ Time Frame: 100 days ]The assessment tool to capture overall nutritional status will be the Patient Generated Subjective Global Assessment (PG-SGA) which has been validated in other cancer patients.
- Incidence of acute Graft Versus Host Disease (GVHD) [ Time Frame: 100 days ]All incidences of Grade II-IV GVHD will be quantified.
- Treatment related morbidities and mortalities [ Time Frame: 100 Days ]Both treatment related morbidities and mortalities will be quantified.
- Quality Of Life Assessment (QOL) [ Time Frame: 100 Days ]The QOL assessment will utilize the FACT-BMT (Functional Assessment of Cancer Therapy Bone Marrow Transplant) assessment tool as well as other patient-reported symptom instruments to capture the patient reported experience.
- Costs of care [ Time Frame: 100 Days ]The mean, median and range of costs will be compared in the three arms.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01725022
|Contact: Krista Rowe, MSN, AOCNS||(919) firstname.lastname@example.org|
|Contact: Martha Lassiter, MSN OCN||(919) email@example.com|
|United States, North Carolina|
|Duke University Medical Center||Recruiting|
|Durham, North Carolina, United States, 27710|
|Contact: Krista Rowe, MSN, AOCNS 919-684-7115 firstname.lastname@example.org|
|Contact: Carolyn McDonald, RN, ONS 919-613-5042 email@example.com|
|Principal Investigator: Nelson Chao, MD, MBA|
|Principal Investigator:||Nelson Chao, MD, MBA||Duke University|